Roivant Sciences (ROIV) Share-based Compensation (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Share-based Compensation came in at $269.0 million in Q4 2025, up 30.87% YoY from $205.5 million in Q4 2024, and up 279.8% on a QoQ basis from $70.8 million in Q3 2025.
Roivant Sciences (ROIV) Share-based Compensation (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Share-based Compensation data on file, last reported at $269.0 million in Q4 2025.
- Quarterly Share-based Compensation rose 30.87% year-over-year to $269.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $627.5 million (up 34.07% YoY) and the FY2026 annual result came in at $346.2 million, up 19.77% from the prior year.
- Share-based Compensation improved to $269.0 million in Q4 2025, from $70.8 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $487.8 million in Q4 2021 to a low of $44000.0 in Q1 2025.
- A 5-year average of $102.1 million and a median of $57.0 million in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2021 — Share-based Compensation soared 3371.89% — and 2025, when it plunged 96.62%.
- Tracing ROIV's Share-based Compensation over 5 years: stood at $487.8 million in 2021, then slumped by 60.54% to $192.5 million in 2022, then decreased by 20.57% to $152.9 million in 2023, then jumped by 34.43% to $205.5 million in 2024, then jumped by 30.87% to $269.0 million in 2025.
- The last three Share-based Compensation figures came in at $269.0 million (Q4 2025), $70.8 million (Q3 2025), and $82.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 83.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 83.34 Mn |
| Jun 30, 2026 | 83.34 Mn |
| Dec 31, 2025 | 269.00 Mn |
| Dec 31, 2025 | 269.00 Mn |
| Sep 30, 2025 | 70.83 Mn |
| Sep 30, 2025 | 70.83 Mn |
| Jun 30, 2025 | 82.18 Mn |
| Jun 30, 2025 | 82.18 Mn |
| Mar 31, 2025 | 44,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | 205.54 Mn |
| Dec 31, 2024 | 205.54 Mn |
| Sep 30, 2024 | 59.44 Mn |
| Sep 30, 2024 | 59.44 Mn |
| Jun 30, 2024 | 50.19 Mn |
| Jun 30, 2024 | 50.19 Mn |
| Mar 31, 2024 | 1.30 Mn |
| Mar 31, 2024 | 1.30 Mn |
| Dec 31, 2023 | 152.90 Mn |
| Dec 31, 2023 | 152.90 Mn |